Abstract
Importance Pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk. However, it is unknown whether breast cancer risk differs by PV type or location in carriers ascertained from the general population.
Objective To evaluate breast cancer risks associated with PV type and location in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
Design Age adjusted case-control association analysis for all participants, subsets of PV carriers, and women with no breast cancer family history in population-based and clinical testing cohorts.
Setting Twelve US population-based studies within the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium, and breast cancer cases from the UK-Biobank and an Ambry Genetics clinical testing cohort.
Participants 32,247 women with and 32,544 age-matched women without a breast cancer diagnosis from CARRIERS; 237 and 1351 women with BRCA2 PVs and breast cancer from the UKBB and Ambry Genetics, respectively.
Exposure(s) PVs in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
Main Outcome(s) and Measure(s) PVs were grouped by type and location within genes and assessed for risks of breast cancer (odds ratios (OR), 95% confidence intervals (CI), and p-values) using logistic regression. Mean ages at diagnosis were compared using linear regression.
Results Compared to women carrying BRCA2 exon 11 protein truncating variants (PTVs) in the CARRIERS population-based study, women with BRCA2 ex13-27 PTVs (OR=2.7, 95%CI 1.1-7.9) and ex1-10 PTVs (OR=1.6, 95%CI 0.8-3.5) had higher breast cancer risks, lower rates of ER-negative breast cancer (ex13-27 OR=0.5, 95%CI 0.2-0.9; ex1-10 OR=0.5, 95%CI 0.1-1.0), and earlier age of breast cancer diagnosis (ex13-27 5.5 years, p<0.001; ex1-10 2.4 years, p=0.17). These associations with ER-negative breast cancer and age replicated in a high-risk clinical cohort and the population-based UK Biobank cohort. No differences in risk or age at diagnosis by gene region were observed for PTVs in other predisposition genes.
Conclusions and Relevance Population-based and clinical high-risk cohorts establish that PTVs in exon 11 of BRCA2 are associated with reduced risk of breast cancer, later age at diagnosis, and greater risk of ER-negative disease. These differential risks may improve individualized risk prediction and clinical management for women carrying BRCA2 PTVs.
Question Does ATM, BRCA1, BRCA2, CHEK2 and PALB2 pathogenic variant type and location influence breast cancer risk in population-based studies?
Findings Breast cancer risk and estrogen receptor status differ based on the type and location of pathogenic variants in BRCA2. Women carrying protein truncating variants in exon 11 have a lower breast cancer risk in the population-based cohorts, older age at diagnosis and higher rates of estrogen receptor negative breast cancer than women with exon 1-10 or exon 13-27 truncation variants in population-based and clinical testing cohorts.
Meaning Incorporating pathogenic variant type and location in cancer risk models may improve individualized risk prediction.
Competing Interest Statement
E.C.P has received research funding from Grail; A.V.P has received institutional funding from Grail; K.R. received research funding from Medtronic and reports family and institution have filed intellectual property for the application of artificial intelligence for diagnosis and risk stratification; J.E.O. has research funding from Exact Sciences; S.M.D. received honoraria from AstraZeneca and GlaxoSmithKline, and institutional research funding from AstraZeneca and Clovis Oncology; J.N.W. was employed by and holds stock options with Natera, consulted for Myriad Genetics, and served on the speaker bureau for AstraZeneca; K.L.N. consulted for Merck, P.K. received travel and accommodation expenses from Regeneron; S.Y. received institutional research funding from Repare Therapeutics and AstraZeneca; F.J.C. received honoraria from Ambry Genetics/Konica Minolta, US Oncology Network, Natera, consulted for AstraZeneca, served on speakers bureaus for Ambry Genetics and Qiagen, and received research funding and travel accommodations and expenses from Grail; R.K., M.E.R., and T.P. are employed by Ambry Genetics.
Funding Statement
Supported by Breast Cancer Research Foundation (K.L.N., F.J.C., S.M.D., and J.M.W.); the Basser Center for BRCA (K.L.N.; S.M.D.); Susan G. Komen Foundation (S.M.D.); The Gray Foundation (K.L.N; S.M.D.); NIH grants R01CA192393 (K.L.N., D.E.G., F.J.C.), R01CA225662 (F.J.C.), and R35CA253187 (F.J.C.); an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer (P50CA116201) to Mayo Clinic; and the Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic (2K12CA090628-21); Penn Center for Global Genomics and Health Equity (M.P.A). Support for the contributing studies was provided by the NIH (R01CA202981, UL1TR000445, U01CA164974, R01CA098663, P01CA87969, UM1CA186107, U19CA148065, UM1CA176726 and U19CA148065; 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005, P30CA014520, Z01-ES044005, Z01-ES102245, and Z01-ES049033); Susan G. Komen Foundation (SAC210105 [BEST], SAC180086 [JRP], FAS703856 [2SISTER]); Lon V. Smith Foundation (LVSF-5682439); and the University of Wisconsin-Madison Office of the Vice Chancellor for Research and Graduate Education (WWHS). The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II cohort (and/or Cancer Prevention Study-3).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The CARRIERS study was approved by the institutional review board at the Mayo Clinic.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos